Monograph Details
|
|
Nutrition
> Obesity
|
|
BONTRIL SLOW RELEASE |
| Manufacturer |
|
Valeant Pharmaceuticals, Inc |
| Legal Classification |
|
CIII |
| Pharmacological Class |
|
Sympathomimetic. |
| Generic Name |
|
Phendimetrazine tartrate 105mg; slow rel caps. |
| Also |
|
• BONTRIL PDM
|
| Indications |
|
Short-term adjunct in managing exogenous obesity. |
| Children |
|
Not recommended. |
| Adults |
|
105mg in the AM, 30–60 minutes before breakfast. |
| Contraindications |
|
Advanced arteriosclerosis. Cardiovascular disease. Moderate or severe hypertension. Hyperthyroidism. Glaucoma. Highly nervous or agitated states. Drug or alcohol abuse. Concomitant CNS stimulants. During or within 14 days of MAOIs (see Interactions). |
| Precautions |
|
Discontinue after a few weeks as tolerance to anorectic effect occurs. Avoid abrupt cessation after prolonged high doses. Mild hypertension. Abuse and dependence potential. Diabetes. Reevaluate after drug-free interval. Prescribe minimal supply to avoid overdose. Pregnancy. |
| Interactions |
|
Hypertensive crisis with MAOIs. May antagonize guanethidine. CNS effects with alcohol, other CNS drugs. |
| Adverse Reactions |
|
Palpitation, tachycardia, hypertension, CNS overstimulation, dry mouth, GI disturbances, urinary frequency, changes in libido. |
| How Supplied |
Tabs—100, 1000
Caps—100 |
|
|
|
|
